» Articles » PMID: 15659218

Prostaglandin D2 Mediates Neuronal Protection Via the DP1 Receptor

Overview
Journal J Neurochem
Specialties Chemistry
Neurology
Date 2005 Jan 22
PMID 15659218
Citations 86
Authors
Affiliations
Soon will be listed here.
Abstract

Cyclo-oxygenases (COXs) catalyze the first committed step in the synthesis of the prostaglandins PGE(2), PGD(2), PGF(2alpha), PGI(2) and thomboxane A(2). Expression and enzymatic activity of COX-2, the inducible isoform of COX, are observed in several neurological diseases and result in significant neuronal injury. The neurotoxic effect of COX-2 is believed to occur through downstream effects of its prostaglandin products. In this study, we examined the function of PGD(2) and its two receptors DP1 and chemoattractant receptor-homologous molecule expressed on Th2 cells (CRTH2) (DP2) in neuronal survival. PGD(2) is the most abundant prostaglandin in brain and regulates sleep, temperature and nociception. It signals through two distinct G protein-coupled receptors, DP1 and DP2, that have opposing effects on cyclic AMP (cAMP) production. Physiological concentrations of PGD(2) potently and unexpectedly rescued neurons in paradigms of glutamate toxicity in cultured hippocampal neurons and organotypic slices. This effect was mimicked by the DP1-selective agonist BW245C but not by the PGD(2) metabolite 15d-PGJ(2), suggesting that neuroprotection was mediated by the DP1 receptor. Conversely, activation of the DP2 receptor promoted neuronal loss. The protein kinase A inhibitors H89 and KT5720 reversed the protective effect of PGD(2), indicating that PGD(2)-mediated neuroprotection was dependent on cAMP signaling. These studies indicate that activation of the PGD(2) DP1 receptor protects against excitotoxic injury in a cAMP-dependent manner, consistent with recent studies of PGE(2) receptors that also suggest a neuroprotective effect of prostaglandin receptors. Taken together, these data support an emerging and paradoxical neuroprotective role of prostaglandins in the CNS.

Citing Articles

L-PGDS-PGD2-DP1 Axis Regulates Phagocytosis by CD36 MGs/MΦs That Are Exclusively Present Within Ischemic Areas After Stroke.

Nakagomi T, Narita A, Nishie H, Nakano-Doi A, Sawano T, Fukuda Y Cells. 2024; 13(20.

PMID: 39451255 PMC: 11505914. DOI: 10.3390/cells13201737.


Prostaglandins in the Inflamed Central Nervous System: Potential Therapeutic Targets.

Sheremeta C, Yarlagadda S, Smythe M, Noakes P Curr Drug Targets. 2024; 25(13):885-908.

PMID: 39177131 PMC: 11774313. DOI: 10.2174/0113894501323980240815113851.


Differential effect of an evolving amyloid and tau pathology on brain phospholipids and bioactive lipid mediators in rat models of Alzheimer-like pathology.

Do Carmo S, Kautzmann M, Bhattacharjee S, Jun B, Steinberg C, Emmerson J J Neuroinflammation. 2024; 21(1):185.

PMID: 39080670 PMC: 11290283. DOI: 10.1186/s12974-024-03184-7.


DP2 receptor activity sensor suited for antagonist screening and measurement of receptor dynamics in real-time.

Kurz M, Ulrich M, Bittner A, Bunemann M Sci Rep. 2024; 14(1):8178.

PMID: 38589416 PMC: 11374897. DOI: 10.1038/s41598-024-58410-2.


Sex-differences in prostaglandin signaling: a semi-systematic review and characterization of PTGDS expression in human sensory neurons.

Shen B, Sankaranarayanan I, Price T, Tavares-Ferreira D Sci Rep. 2023; 13(1):4670.

PMID: 36949072 PMC: 10033690. DOI: 10.1038/s41598-023-31603-x.